Table 2 Result for the secondary study endpoints
ITT (n = 125) | p | PP (n = 96) | p | |||
|---|---|---|---|---|---|---|
Frovatriptan | Rizatriptan | Frovatriptan | Rizatriptan | |||
Pain-free episodes at 2 h | 117 (33) | 141 (39) | NS | 107 (37) | 116 (40) | NS |
Recurrent episodes (IHS) | 25 (21) | 61 (43) | <0.001 | 21 (20) | 40 (35) | <0.05 |
Recurrent episodes (protocol) | 77 (22) | 117 (32) | <0.001 | 61 (21) | 91 (32) | <0.01 |
Sustained pain-free episodes | 92 (26) | 80 (22) | NS | 86 (30) | 76 (26) | NS |
Pain relief episodes at 2 h | 155 (55) | 166 (62) | NS | 129 (61) | 134 (60) | NS |